Medivir recruits a new head of Commercial Operations

Stockholm — Medivir AB (OMX: MVIR) strengthens the executive management team by
recruiting Henrik Krook as Executive VP Commercial. Henrik will be operationally
and strategically responsible for the company's commercial activities, where a
priority is to build a Nordic organisation for the expected launch of
simeprevir.

Henrik Krook comes from Novartis Norway, where he during the last two years has
worked as Country Manager/Commercial Director and also Scandinavian Head of a
team working with marketing and sales of a broad product portfolio. He has more
than 10 years of experience from managerial positions within the pharmaceutical
industry. Henrik has a MS degree in Pharmacy and a PhD degree in Clinical
Immunology from Uppsala University. In addition, he has an Executive MBA from
Stockholm School of Economics. Henrik assumes the position as Executive VP
Commercial in mid-August.

- We are confident that Henrik, with his extensive Nordic experience in
marketing and sales of pharmaceuticals and his strong expertise in the medical
area, will be a great asset to Medivir’s commercial organisation. He will
strengthen the organisation in Sweden and his experience from leading operations
in the other Nordic countries will be important for the establishment of a
Nordic organisation, says Maris Hartmanis, CEO of Medivir.

For more information, please contact:
Maris Hartmanis, CEO Medivir AB, phone +46 (0)8 407 64 30

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor in late phase III clinical development
for hepatitis C that is being developed in collaboration with Janssen R&D
Ireland.

Medivir has also a broad product portfolio with prescription pharmaceuticals in
the Nordics.

For more information about Medivir AB, please visit the Company’s website:
www.medivir.se


Medivir is a collaborative and agile pharmaceutical company with an R&D focus on
infectious diseases and a leading position in hepatitis C. We are passionate and
uncompromising in our mission to develop and commercialize innovative
pharmaceuticals that improve people’s health and quality of life.